The Transplantation Immunology Group is based at the Hampstead Campus and forms part of a large Immunotherapy Programme at UCL. Our research involves both pre-clinical, translational and phase I/II projects that aim to develop innovative strategies to improve the anti-tumour effects of blood and bone marrow transplantation. We work closely with the groups of Professor Hans Stauss/Dr. Emma Morris (Tumour Immunology, Cellular and Gene Therapy), and Dr. Clare Bennett (Dendritic Cell Immunotherapy), with a number of fellows or PhD students working on joint projects. Following blood or bone marrow transplantation, donor T cells that have been infused as part of the graft or given at a later time point, become activated in response to antigenic differences between the donor and the recipient. This effect can be co-opted to generate anti-tumour activity, an effect termed the ‘graft-versus-tumour’ (GVT) response (Figure 1). Alternatively, donor T cells may react against normal tissues, leading to graft-versus-host disease These outcomes depend upon how donor T cells recognize antigen and this, in turn is influenced by nature of the cells presenting antigen (Figure 3). We are interested in how distinct non-haematopoietic and haematopoietic cell populations in the recipient influence the development of donor T cell immunity after transplantation. This research offers the opportunity to develop new approaches to manipulating antigen presentation for therapeutic benefit e.g. following vaccination. Ultimately, durable anti-tumour immunity requires that T cells with anti-tumour reactivity engraft and then persist long-term in the recipient. By exploring clinically relevant models, we are examining the mechanisms that influence the long-term survival of anti-tumour T cells such that they can provide long-term immune surveillance (Figure 4). An improved understanding of the pathways that regulate this property of ‘memory’ is helping us to engineer T cells that can maintain their functions over long periods.